Biotechnology · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Taysha Gene Therapies, Inc. publishes a filing, an earnings call transcript or a press release.
Get TSHA alertsKamran Alam is recorded as CFO at Taysha Gene Therapies, Inc. (TSHA). The newest filing on record that lists Kamran Alam as CFO at Taysha Gene Therapies, Inc. (TSHA) is dated April 22, 2026. The proxy statement of Taysha Gene Therapies, Inc. reports total compensation of $2,146,964 for Kamran Alam in fiscal 2025, including a base salary of $473,331. Disclosed compensation is on record for 6 fiscal years. Kamran Alam has spoken on 17 earnings calls across 1 company, most recently for Taysha Gene Therapies, Inc. on May 15, 2025. Taysha Gene Therapies, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Taysha Gene Therapies, Inc. includes Sean Nolan (CEO and Board Member), Laura Sepp-Lorenzino (Board Member), Sean Stalfort (Board Member) and 1 other.
“Research and development expenses were $15.6 million for the three months ended March 31, 2025 compared to $20.7 million for the three months ended March 31, 2024.”
“Research and development expenses were $66.0 million for the full year ended December 31, 2024, compared to $56.8 million for the full year ended December 31, 2023.”
“Research and development expenses were $14.9 million for the three months ended September 30, 2024, compared to $11.8 million for the three months ended September 30, 2023.”
“Research and development expenses were $15.1 million for the three months ended June 30, 2024 compared to $19.8 million for the three months ending June 30, 2023.”
“Research and development expenses were $20.7 million for the 3 months ended March 31, 2024, compared to $12.5 million for the 3 months ending March 31, 2023.”
Start not stated–present
Last confirmed April 22, 2026
Proxy statement
Start not stated–2020-04-24
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $473,331 | $2,146,964 |
| 2024 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $455,126 | $2,518,777 |
| 2023 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $413,751 | $975,401 |
| 2022 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $401,700 | $1,201,823 |
| 2020 | Rocket Pharmaceuticals, Inc. (RCKT) | Senior Vice President – Finance and Principal Financial Officer | $197,230 | $634,250 |
| 2019 | Rocket Pharmaceuticals, Inc. (RCKT) | Senior Vice President – Finance and Principal Financial Officer | $54,545 | $2,051,457 |